KR100217807B1 - 9-푸리닐 포스폰산 유도체 - Google Patents

9-푸리닐 포스폰산 유도체 Download PDF

Info

Publication number
KR100217807B1
KR100217807B1 KR1019910011290A KR910011290A KR100217807B1 KR 100217807 B1 KR100217807 B1 KR 100217807B1 KR 1019910011290 A KR1019910011290 A KR 1019910011290A KR 910011290 A KR910011290 A KR 910011290A KR 100217807 B1 KR100217807 B1 KR 100217807B1
Authority
KR
South Korea
Prior art keywords
compound
mmol
formula
phenyl
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019910011290A
Other languages
English (en)
Korean (ko)
Other versions
KR920002622A (ko
Inventor
알라지 세르쥬
당쟁 샤를르
Original Assignee
슈테펜엘.네스비트
메렐 다우 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슈테펜엘.네스비트, 메렐 다우 파마슈티칼스 인크. filed Critical 슈테펜엘.네스비트
Publication of KR920002622A publication Critical patent/KR920002622A/ko
Application granted granted Critical
Publication of KR100217807B1 publication Critical patent/KR100217807B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1019910011290A 1990-07-04 1991-07-04 9-푸리닐 포스폰산 유도체 Expired - Fee Related KR100217807B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90401940.3 1990-07-04
EP90401940 1990-07-04

Publications (2)

Publication Number Publication Date
KR920002622A KR920002622A (ko) 1992-02-28
KR100217807B1 true KR100217807B1 (ko) 1999-10-01

Family

ID=8205733

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910011290A Expired - Fee Related KR100217807B1 (ko) 1990-07-04 1991-07-04 9-푸리닐 포스폰산 유도체

Country Status (22)

Country Link
US (2) US5538978A (enExample)
EP (1) EP0465297B1 (enExample)
JP (1) JP3006919B2 (enExample)
KR (1) KR100217807B1 (enExample)
CN (1) CN1031713C (enExample)
AT (1) ATE133678T1 (enExample)
AU (1) AU643533B2 (enExample)
CA (1) CA2045783C (enExample)
DE (1) DE69116750T2 (enExample)
DK (1) DK0465297T3 (enExample)
ES (1) ES2085446T3 (enExample)
FI (1) FI101793B (enExample)
GR (1) GR3019793T3 (enExample)
HU (1) HU208832B (enExample)
IE (1) IE72096B1 (enExample)
IL (1) IL98702A (enExample)
MX (1) MX9203682A (enExample)
NO (1) NO180541C (enExample)
NZ (1) NZ238774A (enExample)
PT (1) PT98198B (enExample)
TW (1) TW199896B (enExample)
ZA (1) ZA914978B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0465297T3 (da) * 1990-07-04 1996-02-19 Merrell Pharma Inc 9-Purinylphosphonsyre-derivater
EP0531597A1 (en) * 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine
US5817661A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5723466A (en) * 1991-12-06 1998-03-03 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5817660A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5817672A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
AU658698B2 (en) * 1991-12-06 1995-04-27 Aventis Pharmaceuticals Inc. Novel trans cyclopentanyl purine analogs useful as immunosuppressants
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
AU690587B2 (en) * 1993-09-17 1998-04-30 Gilead Sciences, Inc. Method for dosing therapeutic compounds
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
MY141789A (en) * 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
AU2002343604C1 (en) 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
NZ535828A (en) 2002-04-26 2007-10-26 Gilead Sciences Inc Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
EA200501676A1 (ru) 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7138401B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
CA2543142A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
CN1906196A (zh) 2003-12-22 2007-01-31 吉里德科学公司 具有hiv和hcv抗病毒活性的4＇－取代的卡波韦－和阿巴卡韦－衍生物以及相关化合物
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
CA2602257A1 (en) * 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
US8158108B2 (en) * 2006-06-28 2012-04-17 S.C. Johnson & Son, Inc. VOC-free compressed gas aerosol compositions
US8178078B2 (en) * 2008-06-13 2012-05-15 S.C. Johnson & Son, Inc. Compositions containing a solvated active agent suitable for dispensing as a compressed gas aerosol
PE20110219A1 (es) 2008-07-08 2011-03-31 Gilead Sciences Inc Sales del compuesto n-[(s)({[(2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il]oxi}metil)fenoxifosfinoil]-l-alaninato de etilo como inhibidores de vih
KR101692133B1 (ko) 2015-01-13 2017-01-02 연세대학교 원주산학협력단 폴리이미드 수용액을 이용한 폴리이미드 성형방법
CN105061504A (zh) * 2015-09-16 2015-11-18 湖南大学 P-炔基磷酸酯类化合物的制备方法
ES2969496T3 (es) 2017-08-01 2024-05-20 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2150570B (en) * 1983-05-24 1987-04-08 Stanford Res Inst Int Novel antiviral agents
CA1288098C (en) * 1984-08-24 1991-08-27 Richard L. Tolman 4-(guanin-9-yl)butanals and their 3-oxa, 3-thia and 2-ene derivatives having antiviral and antitumor activity
US4988702A (en) * 1986-08-26 1991-01-29 Warner-Lambert Company Novel 9-deazaguanines
EP0328834A1 (en) * 1988-02-16 1989-08-23 Merrell Dow Pharmaceuticals Inc. Novel aspartate transcarbamylase inhibitors
EP0335770B1 (en) * 1988-04-01 1997-01-15 Merrell Pharmaceuticals Inc. Novel fluorophosphonate nucleotide derivatives
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
ATE98249T1 (de) * 1988-04-19 1993-12-15 Merrell Dow Pharma Phosphonoalkylpurin-derivate.
EP0338168A1 (en) * 1988-04-19 1989-10-25 Merrell Dow Pharmaceuticals Inc. Phosphonoalkylpurine derivatives
JPH02124898A (ja) * 1988-04-28 1990-05-14 Nippon Kayaku Co Ltd プリン塩基を有する新規化合物、その用途及び中間体
JPH02124897A (ja) * 1988-07-28 1990-05-14 Nippon Kayaku Co Ltd エリスロフラノシルヌクレオシド誘導体の製造法及び新規誘導体
GB8827339D0 (en) * 1988-11-23 1988-12-29 Wellcome Found Antiviral compounds
EP0374096B1 (de) * 1988-12-14 1992-12-02 Ciba-Geigy Ag 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
DK0465297T3 (da) * 1990-07-04 1996-02-19 Merrell Pharma Inc 9-Purinylphosphonsyre-derivater
EP0468119A1 (en) * 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Novel carbocyclic analogs of certain nucleosides
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides

Also Published As

Publication number Publication date
DE69116750T2 (de) 1996-11-14
ES2085446T3 (es) 1996-06-01
ATE133678T1 (de) 1996-02-15
IL98702A0 (en) 1992-07-15
HUT59151A (en) 1992-04-28
NZ238774A (en) 1993-08-26
PT98198B (pt) 1998-12-31
ZA914978B (en) 1992-04-29
MX9203682A (es) 1992-08-01
CA2045783A1 (en) 1992-01-05
IE72096B1 (en) 1997-03-12
IL98702A (en) 1997-02-18
TW199896B (enExample) 1993-02-11
NO912606L (no) 1992-01-06
IE912329A1 (en) 1992-01-15
US5527803A (en) 1996-06-18
FI101793B1 (fi) 1998-08-31
CN1031713C (zh) 1996-05-01
EP0465297A1 (en) 1992-01-08
CN1058021A (zh) 1992-01-22
FI101793B (fi) 1998-08-31
KR920002622A (ko) 1992-02-28
PT98198A (pt) 1992-04-30
JPH04253989A (ja) 1992-09-09
NO912606D0 (no) 1991-07-03
NO180541B (no) 1997-01-27
DE69116750D1 (de) 1996-03-14
EP0465297B1 (en) 1996-01-31
FI913236A0 (fi) 1991-07-03
AU643533B2 (en) 1993-11-18
FI913236L (fi) 1992-01-05
DK0465297T3 (da) 1996-02-19
HU208832B (en) 1994-01-28
GR3019793T3 (en) 1996-07-31
US5538978A (en) 1996-07-23
CA2045783C (en) 2001-09-18
HU912253D0 (en) 1991-12-30
JP3006919B2 (ja) 2000-02-07
AU7941491A (en) 1992-01-09
NO180541C (no) 1997-05-07

Similar Documents

Publication Publication Date Title
KR100217807B1 (ko) 9-푸리닐 포스폰산 유도체
US8569478B2 (en) Modified 4′-nucleosides as antiviral agents
JP3519736B2 (ja) エナンチオマー的に純粋なβ‐Ｄ‐ジオキソラン−ヌクレオシド
HUT62009A (en) Process for producing unsaturated acyclic phosphonate derivatives of purine and pyrimidine and pharmaceutical compositions comprising same as active ingredient
HUT77436A (hu) Purin- és guaninszármazékok, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására
JPH0378370B2 (enExample)
TW202010750A (zh) 外核苷酸酶抑制劑及其使用方法
JP3497505B2 (ja) 抗ウイルス性非環式ホスホノメトキシアルキル置換アルケニル及びアルキニルプリン及びピリミジン誘導体
EP0539487A1 (en) Antiviral phosphono-alken derivatives of purines
KR0139534B1 (ko) 포스포노알킬퓨린 유도체
US5494912A (en) 9-purinyl phosphonic acid derivitives for treating gout
EP0338887B1 (en) Phosphonoalkylpurine derivatives
JP2013503197A (ja) 新規なヌクレオシドホスホネート及びそのアナログ

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

G170 Re-publication after modification of scope of protection [patent]
PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20020531

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030608

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030608